Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology Stock
Morgan Stanley has upgraded Vir Biotechnology ( VIR, Financial) and uplifted its price target for the stock to $20 from "Equal-weight" to "Overweight," sending the stock sharply higher. The stock is currently trading near $12, which suggests it has a 67% upside potential from Morgan's price target of $20.
Morgan Stanley promotes 173 employees to managing director
"Everybody knows you made a mistake. How are you going to deal with that?" ...
Jim Caron of Morgan Stanley Investment Management explains what's behind the steepening yield curve and what it's telling us ...
Morgan Stanleys Chief US Equity Strategist, Mike Wilson, forecasts a volatile first half of 2025, with recovery prospects ...
Morgan Stanley initiated coverage of Palantir Technologies Inc. (NYSE:PLTR) with an underweight rating and $60 price target ...
Citigroup and Bank of America said they were leaving the group earlier this week, and Goldman Sachs and Wells Fargo made the ...
At Morgan Stanley, the new class is the first set of MD promotions under chief executive Ted Pick, who took the helm of the ...
Morgan Stanley closed $8.38 short of its 52-week high ($136.24), which the company achieved on November 25th.
1don MSN
Joseph Moore, Morgan Stanley semiconductor analyst, joins CNBC's 'Squawk Box' to discuss reactions to Jensen Huang's comments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback